Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05998447Phase 2Terminated

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Role: lead

NCT05419362Phase 2Completed

GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

Role: lead

NCT06235541Phase 1Withdrawn

A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors

Role: lead

NCT04601402Phase 1Completed

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

Role: lead

All 4 trials loaded